VOR
Vor Biopharma Inc.
Healthcare — Biotechnology
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $1.15B |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.65 |
| EPS (TTM) | $-70.40 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $37.88 |
| Analysts | 8 |
| Next Earnings | Aug 11, 2026 DMH |
| Indexes | - |
Technical Indicators
| RSI (14) | 64.1 |
| Beta | 1.70 |
| SMA 20 | $19.33 |
| SMA 40 | $17.28 |
| 52-Week High | $50.20 |
| 52-Week Low | $6.50 |
| 50-Day Avg | $16.75 |
| 200-Day Avg | $15.52 |
| Avg Volume | $1.18M |
| Volume | 897.8K |
Performance Analysis
BULLISHVOR shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report